The MiniMed 780G automated insulin delivery system adapts to substantial changes in daily routine: Lessons from real world users during Ramadan

被引：9

作者：

Al-Sofiani, Mohammed E. ^{[1
,2
]}

Petrovski, Goran ^{[3
,4
]}

Al Shaikh, Abdulrahman ^{[5
]}

Alguwaihes, Abdullah ^{[1
,6
]}

Al Harbi, Mohammad ^{[7
]}

Al Mohannadi, Dabia ^{[8
]}

Adjene, Alero ^{[9
]}

Alagha, Abdulmoeen ^{[5
]}

Al Remeithi, Sareea ^{[10
]}

Alamuddin, Naji ^{[11
,12
]}

Arrieta, Arcelia ^{[13
]}

Castaneda, Javier ^{[13
]}

Chaar, Wael ^{[14
]}

van den Heuvel, Tim ^{[13
]}

Cohen, Ohad ^{[13
,15
]}

机构：

[1] King Saud Univ, Coll Med, Dept Internal Med, Riyadh, Saudi Arabia

[2] Johns Hopkins Univ, Div Endocrinol Diabet & Metab, Baltimore, MD USA

[3] Sidra Med, Div Endocrinol, Dept Pediat Med, Doha, Qatar

[4] Weill Cornell Med, Coll Med, Doha, Qatar

[5] King Abdulaziz Univ Hosp, Internal Med & Endocrinol, Jeddah, Saudi Arabia

[6] Dallah Hosp, Diabet Ctr, Riyadh, Saudi Arabia

[7] Minist Hlth, Dept Natl Diabet Ctr, Riyadh, Saudi Arabia

[8] Hamad Med Corp, Dept Med, Div Endocrinol & Diabet, Doha, Qatar

[9] Imperial Coll London, Dept Diabet & Endocrinol, Diabet Ctr, Abu Dhabi, U Arab Emirates

[10] Sheikh Khalifa Med City, Div Pediat Nephrol, Abu Dhabi, U Arab Emirates

[11] King Hamad Univ Hosp, Dept Internal Med, Manama, Bahrain

[12] Med Univ Bahrain, Royal Coll Surg Ireland, Dept Med, Manama, Bahrain

[13] Medtron Int Trading Sarl, Diabet Operat Unit, Tolochenaz, Switzerland

[14] Medtron Saudi Arabia, Diabet Operating Unit, Tolochenaz, Switzerland

[15] Medtron Int Trading Sarl, Diabet Operating Unit, Route Molliau 31, CH-1131 Tolochenaz, Switzerland

来源：

DIABETES OBESITY & METABOLISM | 2024年 / 26卷 / 03期

关键词：

type; 1; diabetes; real-world evidence; insulin therapy; continuous glucose monitoring (CGM);

D O I：

10.1111/dom.15389

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Aim: To report on the effectiveness and safety of the MiniMed 780G automated insulin delivery system in real-world users during the month of Ramadan.Materials and Methods: CareLink Personal data were extracted from MiniMed 780G system users from the Gulf region. Users were included if they had >= 10 days of sensor glucose data during the month of Ramadan 2022 as well as in the month before and after. For the main analysis, continuous glucose monitoring endpoints were aggregated per month and were reported by time of day (daytime: 05.31-18.00 h, and night-time). Additional analyses were performed to study the pace at which the algorithm adapts.Results: Glycaemic control was well kept in the 449 included users (mean sensor glucose = 152.6 +/- 18.7 mg/dl, glucose management indicator = 7.0 +/- 0.4%, time in range = 70.7 +/- 11.0%, time below 70 mg/dl = 2.3 +/- 2.3%). Albeit some metrics differed from the month before (p < .0001 for all), absolute differences were very small and considered clinically irrelevant. During Ramadan, there was no increased risk of hypoglycaemia during daytime (time below 70 mg/dl = 2.3 +/- 2.4%), time in range was highest during daytime (80.0 +/- 10.7%, night: 60.4 +/- 15.3%), while time above 180 mg/dl was highest during night-time (37.3 +/- 16.3%, day: 17.7 +/- 10.7%). The algorithm adapted immediately upon lifestyle change.Conclusion: The MiniMed 780G automated insulin delivery system is effective, safe and fast in adapting to the substantial changes that occur in the lifestyle of people with type 1 diabetes during Ramadan.

引用

页码：937 / 949

页数：13

共 31 条

[31] Time in tight range in automated insulin delivery system users: Real-world data from children and adolescents with type 1 diabetes
Piona, Claudia
Passanisi, Stefano
Bombaci, Bruno
Marigliano, Marco
Lombardo, Fortunato
Mancioppi, Valentina
Morandi, Anita
Maffeis, Claudio
Salzano, Giuseppina
DIABETES OBESITY & METABOLISM, 2024, 26 (10): : 4767 - 4771

← 1 2 3 4 →